|
Gene: IL1R2 |
Gene summary for IL1R2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IL1R2 | Gene ID | 7850 |
Gene name | interleukin 1 receptor type 2 | |
Gene Alias | CD121b | |
Cytomap | 2q11.2 | |
Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | P27930 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7850 | IL1R2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.34e-09 | 7.02e-01 | -0.1808 |
7850 | IL1R2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.66e-12 | 5.45e-01 | -0.1954 |
7850 | IL1R2 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.50e-04 | 1.07e+00 | -0.2602 |
7850 | IL1R2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 8.02e-07 | 9.57e-01 | -0.2196 |
7850 | IL1R2 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.15e-07 | 5.35e-01 | -0.1526 |
7850 | IL1R2 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.30e-03 | 2.67e-01 | -0.1464 |
7850 | IL1R2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.88e-03 | 6.85e-01 | -0.1706 |
7850 | IL1R2 | A015-C-106 | Human | Colorectum | FAP | 3.61e-02 | -8.05e-02 | -0.0511 |
7850 | IL1R2 | LZE2T | Human | Esophagus | ESCC | 3.10e-03 | 1.44e+00 | 0.082 |
7850 | IL1R2 | LZE4T | Human | Esophagus | ESCC | 1.81e-02 | -5.84e-01 | 0.0811 |
7850 | IL1R2 | LZE20T | Human | Esophagus | ESCC | 3.05e-06 | -6.82e-01 | 0.0662 |
7850 | IL1R2 | LZE24T | Human | Esophagus | ESCC | 3.50e-09 | -6.71e-01 | 0.0596 |
7850 | IL1R2 | LZE22D3 | Human | Esophagus | HGIN | 1.44e-09 | 5.86e-01 | 0.0653 |
7850 | IL1R2 | P1T-E | Human | Esophagus | ESCC | 4.27e-03 | -5.49e-01 | 0.0875 |
7850 | IL1R2 | P4T-E | Human | Esophagus | ESCC | 7.75e-13 | -5.65e-01 | 0.1323 |
7850 | IL1R2 | P5T-E | Human | Esophagus | ESCC | 4.16e-22 | -6.77e-01 | 0.1327 |
7850 | IL1R2 | P8T-E | Human | Esophagus | ESCC | 1.85e-13 | -5.70e-01 | 0.0889 |
7850 | IL1R2 | P10T-E | Human | Esophagus | ESCC | 1.23e-41 | 2.45e+00 | 0.116 |
7850 | IL1R2 | P12T-E | Human | Esophagus | ESCC | 1.10e-29 | -5.21e-01 | 0.1122 |
7850 | IL1R2 | P15T-E | Human | Esophagus | ESCC | 2.70e-17 | 2.02e+00 | 0.1149 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045861 | Colorectum | AD | negative regulation of proteolysis | 106/3918 | 351/18723 | 2.33e-05 | 4.57e-04 | 106 |
GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
GO:00458611 | Colorectum | SER | negative regulation of proteolysis | 88/2897 | 351/18723 | 1.74e-06 | 7.50e-05 | 88 |
GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
GO:00458614 | Colorectum | FAP | negative regulation of proteolysis | 68/2622 | 351/18723 | 3.07e-03 | 2.31e-02 | 68 |
GO:005160417 | Esophagus | HGIN | protein maturation | 68/2587 | 294/18723 | 9.77e-06 | 2.86e-04 | 68 |
GO:00164857 | Esophagus | HGIN | protein processing | 49/2587 | 225/18723 | 7.04e-04 | 9.52e-03 | 49 |
GO:004586126 | Esophagus | HGIN | negative regulation of proteolysis | 68/2587 | 351/18723 | 2.21e-03 | 2.28e-02 | 68 |
GO:19033173 | Esophagus | HGIN | regulation of protein maturation | 18/2587 | 67/18723 | 3.52e-03 | 3.24e-02 | 18 |
GO:00109553 | Esophagus | HGIN | negative regulation of protein processing | 10/2587 | 29/18723 | 4.07e-03 | 3.65e-02 | 10 |
GO:19033183 | Esophagus | HGIN | negative regulation of protein maturation | 10/2587 | 29/18723 | 4.07e-03 | 3.65e-02 | 10 |
GO:00706133 | Esophagus | HGIN | regulation of protein processing | 17/2587 | 65/18723 | 6.04e-03 | 4.87e-02 | 17 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
GO:00019595 | Esophagus | ESCC | regulation of cytokine-mediated signaling pathway | 95/8552 | 150/18723 | 9.48e-06 | 9.04e-05 | 95 |
GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
GO:001095511 | Esophagus | ESCC | negative regulation of protein processing | 20/8552 | 29/18723 | 9.66e-03 | 3.34e-02 | 20 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541863 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0521542 | Oral cavity | NEOLP | Prostate cancer | 28/1112 | 97/8465 | 3.15e-05 | 2.57e-04 | 1.62e-04 | 28 |
hsa0516662 | Oral cavity | NEOLP | Human T-cell leukemia virus 1 infection | 50/1112 | 222/8465 | 6.91e-05 | 5.23e-04 | 3.29e-04 | 50 |
hsa0514641 | Oral cavity | NEOLP | Amoebiasis | 26/1112 | 102/8465 | 5.36e-04 | 3.05e-03 | 1.92e-03 | 26 |
hsa0541873 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0521552 | Oral cavity | NEOLP | Prostate cancer | 28/1112 | 97/8465 | 3.15e-05 | 2.57e-04 | 1.62e-04 | 28 |
hsa0516672 | Oral cavity | NEOLP | Human T-cell leukemia virus 1 infection | 50/1112 | 222/8465 | 6.91e-05 | 5.23e-04 | 3.29e-04 | 50 |
hsa0514651 | Oral cavity | NEOLP | Amoebiasis | 26/1112 | 102/8465 | 5.36e-04 | 3.05e-03 | 1.92e-03 | 26 |
hsa0516612 | Stomach | GC | Human T-cell leukemia virus 1 infection | 41/708 | 222/8465 | 9.06e-07 | 1.71e-05 | 1.20e-05 | 41 |
hsa0516613 | Stomach | GC | Human T-cell leukemia virus 1 infection | 41/708 | 222/8465 | 9.06e-07 | 1.71e-05 | 1.20e-05 | 41 |
hsa0541821 | Stomach | CAG with IM | Fluid shear stress and atherosclerosis | 29/640 | 139/8465 | 3.84e-07 | 7.19e-06 | 5.05e-06 | 29 |
hsa0516621 | Stomach | CAG with IM | Human T-cell leukemia virus 1 infection | 38/640 | 222/8465 | 1.33e-06 | 2.12e-05 | 1.49e-05 | 38 |
hsa05146 | Stomach | CAG with IM | Amoebiasis | 15/640 | 102/8465 | 9.37e-03 | 4.97e-02 | 3.48e-02 | 15 |
hsa0541831 | Stomach | CAG with IM | Fluid shear stress and atherosclerosis | 29/640 | 139/8465 | 3.84e-07 | 7.19e-06 | 5.05e-06 | 29 |
hsa0516631 | Stomach | CAG with IM | Human T-cell leukemia virus 1 infection | 38/640 | 222/8465 | 1.33e-06 | 2.12e-05 | 1.49e-05 | 38 |
hsa051461 | Stomach | CAG with IM | Amoebiasis | 15/640 | 102/8465 | 9.37e-03 | 4.97e-02 | 3.48e-02 | 15 |
hsa0541841 | Stomach | CSG | Fluid shear stress and atherosclerosis | 29/633 | 139/8465 | 3.05e-07 | 5.67e-06 | 4.08e-06 | 29 |
hsa051664 | Stomach | CSG | Human T-cell leukemia virus 1 infection | 39/633 | 222/8465 | 3.66e-07 | 6.43e-06 | 4.62e-06 | 39 |
hsa051462 | Stomach | CSG | Amoebiasis | 15/633 | 102/8465 | 8.50e-03 | 4.56e-02 | 3.28e-02 | 15 |
hsa0541851 | Stomach | CSG | Fluid shear stress and atherosclerosis | 29/633 | 139/8465 | 3.05e-07 | 5.67e-06 | 4.08e-06 | 29 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Breast | DCIS |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Cervix | ADJ |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | CRC | MSI-H |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | CRC | MSS |
IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Endometrium | AEH |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Endometrium | AEH |
IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Endometrium | EEC |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Endometrium | EEC |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Esophagus | Healthy |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | GC | ADJ |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | GC | GC |
IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | ADJ |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | ADJ |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | Healthy |
IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | OSCC |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | OSCC |
IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | Precancer |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | Precancer |
IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Lung | AAH |
IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Lung | AAH |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL1R2 | SNV | Missense_Mutation | c.88T>A | p.Phe30Ile | p.F30I | P27930 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-A2-A0T4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD | |
IL1R2 | SNV | Missense_Mutation | rs769630697 | c.86G>A | p.Arg29Gln | p.R29Q | P27930 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IL1R2 | SNV | Missense_Mutation | rs367683772 | c.478N>T | p.Arg160Cys | p.R160C | P27930 | protein_coding | tolerated(0.06) | possibly_damaging(0.724) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
IL1R2 | deletion | Frame_Shift_Del | novel | c.621delT | p.Cys207TrpfsTer3 | p.C207Wfs*3 | P27930 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
IL1R2 | SNV | Missense_Mutation | c.919G>A | p.Glu307Lys | p.E307K | P27930 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
IL1R2 | SNV | Missense_Mutation | c.548N>G | p.Phe183Cys | p.F183C | P27930 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
IL1R2 | SNV | Missense_Mutation | rs759636734 | c.884N>A | p.Arg295His | p.R295H | P27930 | protein_coding | tolerated(0.16) | benign(0.037) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IL1R2 | SNV | Missense_Mutation | novel | c.546N>C | p.Lys182Asn | p.K182N | P27930 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
IL1R2 | SNV | Missense_Mutation | rs759636734 | c.884N>A | p.Arg295His | p.R295H | P27930 | protein_coding | tolerated(0.16) | benign(0.037) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
IL1R2 | SNV | Missense_Mutation | c.13T>C | p.Tyr5His | p.Y5H | P27930 | protein_coding | tolerated(0.44) | possibly_damaging(0.459) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7850 | IL1R2 | DRUGGABLE GENOME | ANAKINRA | ANAKINRA | ||
7850 | IL1R2 | DRUGGABLE GENOME | IL-1 | |||
7850 | IL1R2 | DRUGGABLE GENOME | GSK-1827771 |
Page: 1 |